2007 Sales: $3.1 billion
Market share: 4.2 $
What they have: Abbott has two biotech blockbusters on the market. Humira, a monoclonal antibody, competes with Remicade and Enbrel. It's approved for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis. Synagis treats respiratory syncytial virus, the leading cause of hospitalization in babies under a year.
What to look for: Abbot is exploring new indications for Humira. It's also advancing a new biologic for autoimmune diseases. ABT-847 is in late-stage development for psoriasis and Crohne's disease. In addition, Abbott teamed up with Genentech in 2007 to develop and commercialize ABT-263 and ABT-869. ABT-263 is being tested in cancers and ABT-869 suppresses tumor growth by preventing the growth of new blood vessels that supply the tumor with oxygen and nutrients.